Focuses on developing novel therapies for Alzheimer's disease by targeting amyloid-beta oligomers.
Acumen Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies aimed at combating Alzheimer's disease. Founded in 1996 and headquartered in Charlottesville, Virginia, Acumen Pharmaceuticals focuses on advancing its lead drug candidate, ACU193. ACU193 is a humanized monoclonal antibody currently undergoing Phase I clinical trials, specifically designed to target soluble amyloid-beta oligomers, which are believed to play a crucial role in the pathogenesis of Alzheimer's.
Beyond ACU193, Acumen Pharmaceuticals is actively engaged in expanding its pipeline of potential treatments for Alzheimer's disease. The company remains committed to leveraging its scientific expertise and strategic partnerships to accelerate the development of novel therapies that address the complex challenges associated with neurodegenerative disorders. With a robust research platform and a strong commitment to patient-centered innovation, Acumen Pharmaceuticals aims to make significant strides in improving the lives of individuals affected by Alzheimer's disease.
With over two decades of experience in biopharmaceutical research, Acumen Pharmaceuticals continues to push the boundaries of Alzheimer's disease treatment. Through its pioneering approach and collaborative efforts within the scientific community, the company remains at the forefront of advancing promising therapies that target the underlying mechanisms of this devastating condition.